nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Author Index
|
|
|
|
4 |
8S1 |
p. S389-S412 |
artikel |
2 |
Calendar
|
|
|
|
4 |
8S1 |
p. S413-S414 |
artikel |
3 |
Editorial Board
|
|
|
|
4 |
8S1 |
p. i-ii |
artikel |
4 |
Revised Draft Guidelines for Proteomic Data Publication
|
|
|
|
4 |
8S1 |
p. ix-xi |
artikel |
5 |
Session 2: Bioinformatics
|
|
|
|
4 |
8S1 |
p. S17-S34 |
artikel |
6 |
Session 3: Functional Proteomics-Cell Signaling
|
|
|
|
4 |
8S1 |
p. S35-S43 |
artikel |
7 |
Session 4: Functional Proteomics-Protein-Protein Interactions and Networks
|
|
|
|
4 |
8S1 |
p. S44-S59 |
artikel |
8 |
Session 5: HUPO Initiatives-Antibodies
|
|
|
|
4 |
8S1 |
p. S60-S67 |
artikel |
9 |
Session 6: HUPO Initiatives-Brain
|
|
|
|
4 |
8S1 |
p. S68-S73 |
artikel |
10 |
Session 7: HUPO Initiatives-Glycoproteomics
|
|
|
|
4 |
8S1 |
p. S74-S76 |
artikel |
11 |
Session 8: HUPO Initiatives-Liver
|
|
|
|
4 |
8S1 |
p. S77-S80 |
artikel |
12 |
Session 9: HUPO Initiatives-New Technologies
|
|
|
|
4 |
8S1 |
p. S81-S84 |
artikel |
13 |
Session 10: HUPO Initiatives-Plasma
|
|
|
|
4 |
8S1 |
p. S85-S87 |
artikel |
14 |
Session 11: HUPO Initiatives-Standards
|
|
|
|
4 |
8S1 |
p. S88 |
artikel |
15 |
Session 41: Industry Sponsored Symposia
|
|
|
|
4 |
8S1 |
p. S387-S388 |
artikel |
16 |
Session 1: Invited Speaker Abstracts
|
|
|
|
4 |
8S1 |
p. S1-S16 |
artikel |
17 |
Session 13: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Cancer Proteomics
|
|
|
|
4 |
8S1 |
p. S98-S139 |
artikel |
18 |
Session 14: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Clinical Biomarker Discovery
|
|
|
|
4 |
8S1 |
p. S140-S169 |
artikel |
19 |
Session 15: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Heart & Stroke
|
|
|
|
4 |
8S1 |
p. S170-S176 |
artikel |
20 |
Session 16: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Liver
|
|
|
|
4 |
8S1 |
p. S177-S182 |
artikel |
21 |
Session 17: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Neuroproteomics
|
|
|
|
4 |
8S1 |
p. S183-S196 |
artikel |
22 |
Session 18: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Obesity & Diabetes
|
|
|
|
4 |
8S1 |
p. S197-S200 |
artikel |
23 |
Session 23: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Other
|
|
|
|
4 |
8S1 |
p. S226-S232 |
artikel |
24 |
Session 19: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Other Tissues
|
|
|
|
4 |
8S1 |
p. S201-S209 |
artikel |
25 |
Session 20: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Plasma
|
|
|
|
4 |
8S1 |
p. S210-S215 |
artikel |
26 |
Session 21: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Target Identification and Validation
|
|
|
|
4 |
8S1 |
p. S216-S219 |
artikel |
27 |
Session 22: Medical, Clinical, Pharmaceutical, and Disease Proteomics-Toxicology
|
|
|
|
4 |
8S1 |
p. S220-S225 |
artikel |
28 |
Session 24: Model Organisms-Microbial Proteomes
|
|
|
|
4 |
8S1 |
p. S233-S251 |
artikel |
29 |
Session 25: Model Organisms-Other Non-Mammalian Proteomes
|
|
|
|
4 |
8S1 |
p. S252-S255 |
artikel |
30 |
Session 26: Model Organisms-Plant Proteomes
|
|
|
|
4 |
8S1 |
p. S256-S261 |
artikel |
31 |
Session 39: News Corner
|
|
|
|
4 |
8S1 |
p. S360-S382 |
artikel |
32 |
Session 12: Organellar Proteomics
|
|
|
|
4 |
8S1 |
p. S89-S97 |
artikel |
33 |
Session 40: Other
|
|
|
|
4 |
8S1 |
p. S383-S386 |
artikel |
34 |
Session 27: Post-Translational Modifications-Glycosylation and Glycoproteomics
|
|
|
|
4 |
8S1 |
p. S262-S267 |
artikel |
35 |
Session 28: Post-Translational Modifications-Other Post-Translational Modifications
|
|
|
|
4 |
8S1 |
p. S268-S272 |
artikel |
36 |
Session 29: Post-Translational Modifications-Phosphorylation and Phosphoproteomics
|
|
|
|
4 |
8S1 |
p. S273-S284 |
artikel |
37 |
Session 30: Proteomics in Biotechnology
|
|
|
|
4 |
8S1 |
p. S285-S289 |
artikel |
38 |
Session 31: Proteomics Technologies-2D Electrophoresis
|
|
|
|
4 |
8S1 |
p. S290-S298 |
artikel |
39 |
Session 33: Proteomics Technologies-Mass Spectrometry-based Quantitative Proteomics
|
|
|
|
4 |
8S1 |
p. S314-S329 |
artikel |
40 |
Session 32: Proteomics Technologies-Mass Spectrometry Technology
|
|
|
|
4 |
8S1 |
p. S299-S313 |
artikel |
41 |
Session 34: Proteomics Technologies-Nanotechnology/Protein Arrays
|
|
|
|
4 |
8S1 |
p. S330-S338 |
artikel |
42 |
Session 37: Proteomics Technologies-Other
|
|
|
|
4 |
8S1 |
p. S351-S357 |
artikel |
43 |
Session 36: Proteomics Technologies-Protein Chemistry
|
|
|
|
4 |
8S1 |
p. S348-S350 |
artikel |
44 |
Session 35: Proteomics Technologies-Protein Prefractionation Technologies
|
|
|
|
4 |
8S1 |
p. S339-S347 |
artikel |
45 |
Session 38: Structural Proteomics
|
|
|
|
4 |
8S1 |
p. S358-S359 |
artikel |